CD22 and systemic mastocytosis: Similar percentages of CD22+ cases were found among all distinct diagnostic subtypes of SM (range: 75% to 90% of CD22+ cases) but MCL, which showed a lower rate of positivity (25%, p ≤ 0.03 vs. ISM groups) (Table 2).